BIOLASE (BIOL) Competitors $0.01 0.00 (-16.69%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BIOL vs. NVIVQ, LGMK, DYNT, CUTR, SONX, GMVDF, SDCCQ, VRAYQ, AHPI, and NMRDShould you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Invivo Therapeutics (NVIVQ), LogicMark (LGMK), Dynatronics (DYNT), Cutera (CUTR), Sonendo (SONX), G Medical Innovations (GMVDF), SmileDirectClub (SDCCQ), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), and Nemaura Medical (NMRD). These companies are all part of the "medical equipment" industry. BIOLASE vs. Invivo Therapeutics LogicMark Dynatronics Cutera Sonendo G Medical Innovations SmileDirectClub ViewRay Allied Healthcare Products Nemaura Medical BIOLASE (NASDAQ:BIOL) and Invivo Therapeutics (NASDAQ:NVIVQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Do analysts recommend BIOL or NVIVQ? BIOLASE presently has a consensus price target of $1.20, indicating a potential upside of 9,515.38%. Given BIOLASE's stronger consensus rating and higher possible upside, research analysts clearly believe BIOLASE is more favorable than Invivo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Invivo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, BIOL or NVIVQ? Invivo Therapeutics has lower revenue, but higher earnings than BIOLASE. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBIOLASE$48.83M0.01-$20.63M-$14.940.00Invivo TherapeuticsN/AN/A-$10.49MN/AN/A Does the MarketBeat Community favor BIOL or NVIVQ? BIOLASE received 292 more outperform votes than Invivo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformBIOLASEOutperform Votes29251.59% Underperform Votes27448.41% Invivo TherapeuticsN/AN/A Does the media prefer BIOL or NVIVQ? In the previous week, BIOLASE had 2 more articles in the media than Invivo Therapeutics. MarketBeat recorded 2 mentions for BIOLASE and 0 mentions for Invivo Therapeutics. BIOLASE's average media sentiment score of 0.00 equaled Invivo Therapeutics'average media sentiment score. Company Overall Sentiment BIOLASE Neutral Invivo Therapeutics Neutral Do institutionals & insiders have more ownership in BIOL or NVIVQ? 8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 12.3% of Invivo Therapeutics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 2.5% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is BIOL or NVIVQ more profitable? Invivo Therapeutics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Invivo Therapeutics' return on equity of 0.00% beat BIOLASE's return on equity.Company Net Margins Return on Equity Return on Assets BIOLASE-41.65% -1,782.73% -55.31% Invivo Therapeutics N/A N/A N/A Which has more volatility & risk, BIOL or NVIVQ? BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. SummaryBIOLASE beats Invivo Therapeutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get BIOLASE News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOL vs. The Competition Export to ExcelMetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$417,000.00$3.64B$5.64B$8.06BDividend YieldN/A2.17%4.57%4.01%P/E Ratio0.0036.2123.1319.03Price / Sales0.011.39383.8993.17Price / CashN/A6.5738.1634.64Price / Book-0.180.716.944.33Net Income-$20.63M-$146.24M$3.20B$247.06M7 Day PerformanceN/A0.85%-2.33%-0.37%1 Month PerformanceN/A-8.15%2.84%-3.85%1 Year PerformanceN/A224.50%10.74%1.27% BIOLASE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOLBIOLASE0.7793 of 5 stars$0.01-16.7%$1.20+9,515.4%-93.5%$417,000.00$48.83M0.00160Analyst ForecastNews CoverageNVIVQInvivo TherapeuticsN/A$0.37flatN/AN/A$1.15MN/A0.006High Trading VolumeLGMKLogicMark0.4271 of 5 stars$0.18+3.7%N/A-99.8%$919,000.00$10.08M0.0020Short Interest ↑Positive NewsGap DownHigh Trading VolumeDYNTDynatronicsN/A$0.10-13.2%N/A-77.0%$899,000.00$33.60M-0.12200Analyst ForecastGap DownCUTRCutera2.0131 of 5 stars$0.04-63.9%$3.00+7,592.3%-97.2%$787,000.00$155.21M-0.01460Analyst ForecastGap DownHigh Trading VolumeSONXSonendoN/A$1.81+1.7%N/A+1,503.8%$773,000.00$44.40M-0.03250News CoverageGMVDFG Medical InnovationsN/A$0.00flatN/A-98.7%$52,000.00$4.42M0.0072SDCCQSmileDirectClubN/A$0.00flatN/A-90.0%$40,000.00$470.74M0.002,700VRAYQViewRayN/AN/AN/AN/A$18,000.00$102.21M0.00300Gap UpHigh Trading VolumeAHPIAllied Healthcare ProductsN/AN/AN/AN/A$16,000.00$27.05M0.00150Gap UpNMRDNemaura MedicalN/A$0.00flatN/A-99.8%$8,000.00$3,017.000.0040 Remove Ads Related Companies and Tools Related Companies Invivo Therapeutics Alternatives LogicMark Alternatives Dynatronics Alternatives Cutera Alternatives Sonendo Alternatives G Medical Innovations Alternatives SmileDirectClub Alternatives ViewRay Alternatives Allied Healthcare Products Alternatives Nemaura Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOL) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIOL Stock Free BIOL Stock Alerts